Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
| ▸ | SLC11A2 | P49281 | 2/20 | 0.51 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.50 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.50 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.50 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.50 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.50 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.50 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.50 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22275785 | 0.98 | BACE1 (0.69) | BACE1HTTHPGDIDO1SMN1; SMN2 | |
| SCHEMBL13007602 | 0.88 | BACE1 (0.77) | BACE1HTTHPGDIDO1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2891486 | 0.86 | BACE1 (0.75) | BACE1HTTHPGDIDO1SMN1; SMN2 | |
| Bromide SCHEMBL3595630 | 0.85 | BACE1 (0.55) | BACE1HTTHPGDIDO1SMN1; SMN2 | |
| Bromide SCHEMBL4919108 | 0.84 | IDO1 (0.61) | BACE1HTTHPGDIDO1SMN1; SMN2 | |
| SCHEMBL13007585 | 0.82 | IDO1 (0.62) | BACE1HTTHPGDIDO1SMN1; SMN2 | |
| SCHEMBL3681446 | 0.80 | HTT (0.61) | BACE1HTTHPGDIDO1SMN1; SMN2 | |
| Bromide SCHEMBL4445136 | 0.78 | HTT (0.62) | HTTHPGDIDO1SMN1; SMN2LMNA | |
| Bromide SCHEMBL2810146 | 0.78 | IDO1 (0.71) | HTTHPGDIDO1SMN1; SMN2LMNA | |
| SCHEMBL3690551 | 0.76 | HTT (0.65) | HTTHPGDIDO1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092020-A1 | IDO/TDO Inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12209079-B2 | IDO/TDO inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-01-28 | — | — | US | disclosed |
| US-20220380305-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. | 2022-12-01 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| WO-2019078246-A1 | IDO/TDO INHIBITOR | 一般社団法人ファルマバレープロジェクト支援機構 | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209079-B2 | IDO/TDO inhibitor | IDO1, IDO2, TDO2 | BACE1 320/4885HTT 71/4885HPGD 1152/4885 |
| US-20200239452-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | BACE1 320/4885HTT 71/4885HPGD 1152/4885 |
| US-20250092020-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | BACE1 320/4885HTT 71/4885HPGD 1152/4885 |
| US-20220380305-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | BACE1 760/4885HTT 100/4885HPGD 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.